The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s ...
Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.
As clinical trials grow more complex, so does the volume of data that requires medical and operational review. Phase III trials now generate an average of 3.6 million data points—three times the ...
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of ...
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly ...
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results